Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
PMID 35441470
Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members
Do not use in conjunction with alcohol
ParkYMChoiJEKangSGKooSHKimLGeumDet al
Disregard those figures and go by the schedule printed on your own pharmacy label, which your prescriber sets for you individually
Ozempic face is a term used to describe facial changes that can occur due to rapid weight loss with Ozempic use, including loss of volume, sagging skin, and increased wrinkles
